Digital biomarkers hold promise for healthcare, offering improved rare disease detection and cost reduction, with the potential for future implementation in clinical healthcare settings.

Digital pathology could enable the integration of biomarkers to enhance therapy effectiveness, potentially improving the capabilities of pathologists through AI-powered tools.

While the integration of AI in digital pathology will require a concerted push from those in the industry, the ability to rapidly process large amounts of tissue data with a high degree of accuracy makes it a potentially invaluable resource for diseases which are highly heterogeneous.

Beverley Patterson, Clinical Science Director at Ono Pharma UK Ltd, leads a Discussion Group on harnessing biomarker technologies to improve disease detection and tracking.

Smartphones, laptops and other household electronic devices could be optimised for the early detection of neurodegenerative diseases such as Alzheimer’s. Preventative monitoring approaches such as these could provide another avenue of detection to abet the provision of treatment.

How can the spatial interactions of the tumour immune microenvironment reveal prognostic insights into Follicular Lymphoma? We ask Martin Fergie, Lecturer in Healthcare Sciences at the University of Manchester.

This Commentary article explores the applications of pathway mining for the identification of disease targets associated with breast cancer, where there is an unmet need for treatment. The mission is to identify the best proliferation marker for guiding the choice of systemic treatments for breast cancer.

This commentary article looks at the latest applications in digital and wearable biomarkers, with industry and academic insights from GlaxoSmithKline, Roche, and University College London.